Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
A phase 1/2 trial of Bevacizumab in cervical cancer, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.
Overview
Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer is a phase 1/2 interventional study registered as NCT07080216 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 120 participants planned, started 2025-09-23 and due to reach its primary completion in 2027-08. Interventions recorded: ZG005, Gecacitinib, Bevacizumab. Conditions listed: Cervical Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
- TrialStudy of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
- TrialStudy of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
- TrialA Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
Shares Bevacizumab, Cervical cancer.
- TrialBAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer
Shares Bevacizumab, Cervical cancer.
- TrialA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc
Shares Bevacizumab, Cervical cancer.
- TrialSHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Shares Bevacizumab, Cervical cancer.
- TrialBEATcc / ENGOT-Cx10 / GOG-3030
Shares Bevacizumab, Cervical cancer.